New insights into the binding of PF4 to long heparin oligosaccharides in ultralarge complexes using mass spectrometry

J Thromb Haemost. 2023 Dec;21(12):3608-3618. doi: 10.1016/j.jtha.2023.08.020. Epub 2023 Aug 28.

Abstract

Background: Heparin-induced thrombocytopenia (HIT) is a serious complication caused by heparin drugs. The ultralarge complexes formed by platelet factor 4 (PF4) with heparin or low molecular weight heparins (LMWHs) are important participants in inducing the immune response and HIT.

Objectives: We aim at characterizing the interaction between PF4 and long-chain heparin oligosaccharides and providing robust analytical methods for the analysis of PF4-heparin complexes.

Methods: In this work, the characteristics of PF4-enoxaparin complexes after incubation in different molar ratios and concentrations were analyzed by multiple analytical methods, especially liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry with multiple reaction monitoring were developed to qualitatively and quantitatively monitor heparin oligosaccharides and PF4 in HIT-inducing complexes.

Results: The results showed that the largest proportion of ultralarge complexes formed by PF4 and enoxaparin was at a specific molar ratio, ie, a PF4/enoxaparin ratio of 2:1, while the ultralarge complexes contained PF4 tetramer and enoxaparin at a molar ratio of approximately 2:1.

Conclusion: A binding model of PF4 and enoxaparin in ultralarge complexes is proposed with one heparin oligosaccharide chain (∼ dp18) bound to 2 PF4 tetramers in different morphologies to form ultralarge complexes, while PF4 tetramer is surrounded by multiple heparin chains in smaller complexes. Our study provides new insights into the structural mechanism of PF4-LMWH interaction, which help to further understand the mechanism of LMWH immunogenicity and develop safer heparin products.

Keywords: low molecular weight heparin; mass spectrometry; molecular docking simulation; platelet factor 4; thrombocytopenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Enoxaparin / adverse effects
  • Heparin*
  • Heparin, Low-Molecular-Weight / adverse effects
  • Humans
  • Immunologic Factors / adverse effects
  • Mass Spectrometry
  • Oligosaccharides / adverse effects
  • Platelet Factor 4*
  • Thrombocytopenia* / chemically induced

Substances

  • Enoxaparin
  • Heparin
  • Heparin, Low-Molecular-Weight
  • Immunologic Factors
  • Oligosaccharides
  • Platelet Factor 4
  • PF4 protein, human